RNS Number : 1009K
Citadel Group
03 December 2025
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser
Citadel Group
(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a) The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named.
N/A
(c) Name of offeror/offeree in relation to whoserelevant securities this form relates Use a separate form for each offeror/offeree
MURAL ONCOLOGY PLC
(d) If an exempt fund manager connected with anofferor/offeree, state this and specify identityof offeror/offeree(Note 1)
N/A
(e) Date position held/dealing undertaken For an opening position disclosure, state thelatest practicable date prior to the disclosure
2 December 2025
(f) In addition to the company in 1(c) above, is thediscloser also making disclosures in respectof any other party to the offer? If it is a cash offer or possible cash offer, state"N/A"
N/A
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security(Note 3)
Common Stock ISIN IE000LK2BOB4 $0.01 ordinary shares
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled
264,246
1.52
0
0.00
(2) Cash-settled derivatives
0
0.00
0
0.00
(3) Stock-settled derivatives(including options) andagreements to purchase/sell
12,300
0.07
211,300
1.21
Total
276,546
1.59
211,300
1.21
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit(Note 5)
Common
Buy Transaction
105
2.0200 USD
Common
Buy Transaction
580
2.0201 USD
Common
Buy Transaction
11
2.0209 USD
Common
Buy Transaction
100
2.0211 USD
Common
Buy Transaction
1,020
2.0212 USD
Common
Buy Transaction
6,750
2.0214 USD
Common
Buy Transaction
621
2.0215 USD
Common
Buy Transaction
3
2.0300 USD
Common
Sell Transaction
2,322
2.0200 USD
Common
Sell Transaction
3,375
2.0214 USD
Common
Sell Transaction
1,729
2.0221 USD
Common
Sell Transaction
18,298
2.0225 USD
Common
Sell Transaction
5
2.0260 USD
Common
Sell Transaction
31
2.0277 USD
Common
Sell Transaction
744
2.0290 USD
Common
Sell Transaction
1,400
2.0299 USD
Common
Sell Transaction
419
2.0300 USD
Ap29
(b) Cash-settled derivative transactions
Class ofrelevantsecurity
Productdescriptione.g. CFD
Nature of dealinge.g. opening/closing a long/short position,increasing/ reducing a long/ short position
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class ofrelevantsecurity
Nature of dealinge.g. subscription,conversion, exercise
Details
Price per unit (ifapplicable)(Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreementor understanding, formal or informal, relating to relevant securitieswhich may be an inducement to deal or refrain from dealingentered into by the person making the disclosure and any party tothe offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. Ifthere are no such agreements, arrangements or understandings, state"none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understandingbetween the person disclosing and any other person relatingto the voting rights of any relevant securities under any optionreferred to on this form or relating to the voting rights or futureacquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, thisshould be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached?
YES
Date of disclosure
3 December 2025
Contact name
Paula Santos
Telephone number
020 7645 9700
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person makingdisclosure:
Citadel Group
Name of offeror/offeree in relationto whose relevant securities thedisclosure relates:
MURAL ONCOLOGY PLC
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class ofrelevantsecurity
Productdescriptione.g. calloption
Written orpurchased
Number ofsecurities to which option or derivativerelates
Exercisepriceper unit
Typee.g.American,Europeanetc.
Expirydate
Common
Call Option
Purchased
800
5.0 USD
American
19/12/2025
Common
Put Option
Purchased
-80,700
2.5 USD
American
15/01/2027
Common
Put Option
Purchased
-3,100
2.5 USD
American
19/12/2025
Common
Call Option
Purchased
900
5.0 USD
American
20/03/2026
Common
Call Option
Purchased
8,600
2.5 USD
American
20/03/2026
Common
Call Option
Purchased
2,000
7.5 USD
American
20/03/2026
Common
Call Option
Sold
-32,000
2.5 USD
American
19/12/2025
Common
Call Option
Sold
-49,100
5.0 USD
American
15/01/2027
Common
Call Option
Sold
-46,400
2.5 USD
American
15/01/2027
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest orposition can be fully understood:
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)
Class of relevant security inrelation to which subscriptionright exists:
Details, including nature of therights concerned and relevantpercentages:
It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ITPPKNBNDBDDBBK
